Translational Genomics Research Institute

PacBio reported a 11% Q3 2024 revenue increase to $40 million, driven by new product launches including the upgraded Revio platform and the Vega benchtop sequencer. Despite a year-over-year revenue decrease, the company remains committed to becoming cash flow positive by 2026, supported by strategic partnerships and cost reductions. PacBio expects Q4 revenue to be flat to slightly up, with a full-year forecast below $170 million.

Moleculin Biotech appoints Dr. Daniel D. Von Hoff to its Annamycin Scientific Advisory Board, recognizing his expertise in pancreatic cancer and his enthusiasm for Annamycin's potential in treating various cancers.

Nautilus Biotechnology reports Q3 2024 financial results: operating expenses $19.1M, net loss $16.4M, cash, cash equivalents, and investments $221.2M. CEO Sujal Patel highlights progress in proteomics and positive feedback from researchers.

Soteria Precision Medicine Foundation partners with TGen to provide precision medicine navigation for Special Operation Forces (SOF) members with cancer, focusing initially on solid tumors and later expanding to broader armed forces. The collaboration aims to enhance cancer care through comprehensive genomic profiling and advanced analytics, improving patient outcomes and supporting care teams.